Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Investor Presentation

Emcure Ref: EPL/CS/SE/0085/2026 Date: September 25, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, P J Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400 051 Mumbai- 400 001 Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE Dear Sir/Madam, Subject: Intimation under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 – ‘Investor Presentation’ Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the ‘Investor Presentation’. The same is also available on the Company’s website i.e., www.emcure.com. This is for your information and record. Thanking you, For Emcure Pharmaceuticals Limited Amruta Yangalwar Company Secretary & Compliance Officer ICSI Membership Number: A25687 Encl.: As above Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 Complex Science. Disciplined Execution. Compounding Value. Investor Presentation September 2026 USD 1Bn+ +16.6% 33.1% Operating Revenue Revenue growth PAT Growth (FY26) FY26 FY26 ▲120 bps YoY Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute “forward-looking statements.” These statements are based on Emcure Pharmaceuticals Limited’s current expectations, assumptions, and projections about future events. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. Such statements may include, but are not limited to, references to Emcure’s business strategy, expansion plans, R&D pipeline, regulatory developments, financial performance, operational efficiencies, market conditions, and other future events. Words such as “expects,” “anticipates,”“intends,” “plans,”“believes,” “may,”“will,” “should,” andsimilarexpressionsare intended to identify forward-looking statements. These risks and uncertainties include regulatory changes, competitive pressures, technology changes, supply chain challenges, currency fluctuations, ability to obtain or maintain approvals, product commercialisation timelines, and other risks inherent to the pharmaceutical industry. This presentation is for general information only and does not constitute an offer, invitation, solicitation, or recommendation to buy, sell, or subscribe to any securities of Emcure Pharmaceuticals Limited. Product information, including molecules under development or awaiting approval, is for representation purposes only. Availability of products may vary by geography depending on regulatory approvals and patent status. Thispresentation is not intended to providemedicaladvice. TheCompany undertakes no obligation to update or reviseany forward-looking statements basedon newinformation or future events. Contents Company Overview A diversified pharmaceutical company India Business II 9 Scaled, chronic-led domestic franchise International Business III 22 Europe, Canada and RoW Research & Development IV 27 Differentiated R&D platforms Manufacturing V 30 Compliant, complex manufacturing scale Sustainability VI 32 Responsible growth Governance & Leadership VII 34 Board of Directors and Leadership Appendix VIII 37 Financials FY26 and Q1 FY27 Company Overview A diversified pharma company with scale in India and differentiated international businesses A Diversified Pharma Company With Scale in India and Differentiated International Businesses USD 1Bn+ 44%/ 56% 10/32 19/20 Scale Revenue from Operations Domestic/ International Split Brand families with revenue > Top Brands ranked top 3 in (FY26)@ (FY26) INR 1,000/500 Mn* their category #2 #13 #9 ~50% Domestic Rank in Gynaecology Largest player* Rank by market share in Revenue share from complex covered market* products# ~30% 20% / 16% / 20% 80+ 900+ International Revenue share from complex Revenue contribution — Countries Products launched products# Europe / Canada / RoW @ As per average exchange rate for FY26 *by value, IQVIA Mar-26 #Complex products include iron, chiral, biotherapeutics, injectables and photo-chemistry products Our Journey: 1981 to 2026 1981 1995 2001/02 2006 2007 Emcure Pharmaceuticals Started focusing on Indian Incorporated Gennova and Blackstone’s first investment in Launched firstbiosimilar of incorporated domestic branded generics Zuventus India; began limited EM sales Tenecteplase 2024 2020 2015 2014 Listed on NSE and BSEon 10 July US business de-merger Entry into Canada through Marcan Bain acquired Blackstone’s stake; 2024 acquisition acquiredTillomed UK 2024 2024 2025 2026 Distribution agreement with Sanofi Entered Consumer Wellness and Partnered with Novo Nordisk for Partnered with Roche to for cardiac portfolio with Dermatologysegment Poviztra® (semaglutide); acquired strengthen nephrology and extension to OAD*in 2025 Manx Healthcare transplant care in India *OAD: Oral Anti-Diabetic Drug Profitable Growth Delivering Stronger Returns A diversified growth platform with earnings growth ahead of revenue 1. Strong top-line growth… 2. …Driving OperationalLeverage… ▲17.6% CAGR over FY24–FY26 +90 bps margin gain Revenue (INR Mn) and YoY growth (%) EBITDA* (INR Mn) and margin (%) 19.4% 92,035 18.6% 78,960 18.5% 66,583 17,886 14,689 12,297 FY24 FY25 FY26 FY24 FY25 FY26 3. …Leading to 33.6% earnings CAGR ▲+230 bps PAT margin 4. …and 23%+ Return on Capital ▲+430 bps vs FY24 PAT (INR Mn) and margin (%) RoCE#(%) 9.0% 10.2% 23.7% 7.9% 22.0% 19.4% 9,413 7,075 5,276 FY24 FY25 FY26 FY24 FY25 FY26 *“EBITDA” is defined as earnings before interest, taxes, depreciation and amortisation, excluding other income and Net (gain) / loss on foreign currency transactions #“RoCE” refers to Return on Capital Employed, and is calculated by dividing EBIT for a given year by Capital Employed (i.e., total equity plus Net Debt) as of the end of that year Three Strategic Priorities Underpin the FY26-FY30 Growth Aspiration 01 Deepen the Domestic 02 Scale differentiated 03 Translate Differentiated R&D Franchise international portfolios platforms into Commercial launches Strengthening the India business through: Expanding international through calibrated Progress near-term assets across obesity, ophthalmology, front-end expansion oncology, anti-infectives and HIV Deeper presence in Women’s health, Accelerate the growth of Continue investing in the following platforms cardio-metabolic, CNS, Super Specialty differentiated in-house launches Biologics Novel Drug Delivery EU: complex injectables and specialty Sharper commercial execution System (NDDS) generics Canada: Gain market share through pan- Scale dermatology and consumer Canadian front-end presence Complex Injectables Long-Acting Injectables (LAI) Targeted in-licensing to augment in- RoW: Product portfolio to drive front- housedevelopment end expansion strategy Antibody-Drug Conjugates (ADC) India Business A scaled India franchise with rising chronic exposure and multiple growth vectors A Chronic-Led Franchise Positioned for Acceleration Brand leadership, increasing chronic exposure and science-led approach create multiple independent growth vectors. DOMESTIC REVENUE CHRONIC MIX# BRAND LEADERSHIP SCALE ANCHORS MR STRENGTH INR 40,270 Mn 60%+* 19/20 ~50% 4,000+ +10.0% YoY ~46% in FY23 Top 3# in their category of India sales Field force FY26 revenue A structurally higher-quality mix Depth across therapy areas Complex products Pan-Indian presence in metros and tier 1 and tier 2-6 cities CVM#increasedby 460 bps over FY24-26 BRAND SCALE: Number of Brands >INR 500 Mn# PCPM (INR Lacs/MR/Month) improved by ~30% FY24-26 60.1% 55.5% FY [Showing first 8,000 characters — download PDF for full document]